RIPK3 and melanoma: We report here that although cotreatment with HDAC and BRAF inhibitors activates the caspase cascade and the mitochondrial apoptotic signaling, it kills BRAFV600E melanoma cells predominantly by induction of necrosis in a RIPK1- and RIPK3-independent manner.